Genzyme (GENZ) CEO Dumps 200K Shares As Company Deals With Manufacturing Issues
More News related to GENZ
- Goldman Sachs Removed Genzyme (GENZ) from Conviction Sell List, Adds St. Jude (STJ)
- Scott Canute Joins Genzyme to Head Manufacturing and Corporate Operations
- UBS Upgrades Genzyme (GENZ) to Buy, Boosts Target to $68
- Morgan Joseph Adds Spectrum Pharmaceuticals (SPPI) to Trading List; Expect Strong Growth From Zevalin
- Genzyme Strengthens Role of Board's Lead Independent Director
More News related to Insider Trades
- Furniture Brands (FBN) CEO Buys 50K Shares, Other Execs Also Buy
- Greenbrier (GBX) CEO Buys 15K Shares
- Micrel (MCRL) CEO Buys 40K Shares, CFO Buys 7.5K Shares
- Health Management Associates (HMA) CFO Curry Buys 10K Shares
- FMC Corp (FMC) CEO Buys $1M In Open Market Trades
Genzyme Corp. (Nasdaq: GENZ) Chairman/CEO, Henri A. Termeer, disclosed the sale of 200,000 shares on 11/523 at $50.47, after exercising options on the same number of shares at $26.50.
The options were set to expire 05/25/2010 and the sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2009.
With shares of GENZ down 23% YTD on manufacturing issues, the insider sale will not likely be greeted kindly by investors.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Insider TradesStocks Mentioned
+0.38Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
